About Aprea Oncology
Aprea Oncology handles US commercial development and partnerships for APR-246 (eprenetapopt) and next-generation p53-targeting compounds for myeloid and solid tumors.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Aprea Oncology. Response typically within 48 hours.
